- Details
- Zach Klaassen joins Alicia Morgans in discussing an underestimated topic of mental health and its effects on patients with genitourinary cancers. Drs. Klaassen and Morgans discuss hypothesis-generating population-level data in this landscape and talk through the importance of supporting these patients and using what Dr. Klaassen refers to as clinical intuition and asking follow-up questions when s...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the publication in the Lancet analyzing new data from the STAMPEDE trial of two randomized controlled phase 3 trials done in a multiarm, multistage platform protocol to assess the efficacy of adding abiraterone and prednisolone alone or with enzalutamide to androgen-deprivation therapy (ADT) in men with high-risk non-metastatic prostate cancer. Biogr...
|
- Details
- David Penson joins Alicia Morgans to discuss the rapidly changing landscape in prostate cancer, focusing on how imaging and therapeutic advances have disrupted the landscape in the nonmetastatic castration-resistant prostate cancer (CRPC) setting. Dr. Penson highlights advancements in PSMA scanning and how it impacts potential study inclusion criteria. Drs. Morgans and Penson also discuss PSMA PET...
|
- Details
- Alicia Morgans is joined by Christian Gratzke to discuss data presented at the European Society of Medical Oncology (ESMO) 2021 annual meeting around the time course profile of adverse events with darolutamide in the ARAMIS phase 3 trial. The ARAMIS trial was a phase three multicenter randomized control trial, comparing darolutamide versus placebo in combination with ADT in non-metastatic castrati...
|
- Details
- Alicia Morgans is joined by Neal Shore to discuss his presentation from the 2021 American Urologic Association (AUA) annual meeting on the relationship between PSA response and urinary and bowel adverse events (AEs), time to deterioration in the quality of life, and prostate cancer related invasive procedures in the ARAMIS trial. The authors examined the proportion of darolutamide patients achievi...
|
- Details
- Gerhardt Attard joins Alicia Morgans to discuss a combined analysis from two comparisons in the STAMPEDE platform. Dr. Gerhardt Attard presented a combined analysis from the STAMPEDE platform assessing the role of abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0...
|
- Details
- Importance of early intervention in nmCRPC—A discussion with Karim Fizazi, MD, PhD. Darolutamide, an androgen receptor inhibitor, was developed to improve the safety profile of apalutamide and enzalutamide. It has a distinct structure that offers low penetration of the blood-brain barrier as well as other characteristics with the potential for fewer and less toxic adverse events (AEs). The primary...
|
- Details
- In this discussion, Stephen Freedland, MD, joins Alicia Morgans, MD, MPH, to discuss a health economics study that was recently published titled, Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer. The objective of this study was to evaluate the association of prostate-specific antigen doubling time (PS...
|
- Details
- In this Journal Club, Christopher Wallis and Zachary Klaassen discuss the updated analysis in the most recent publication of the ARAMIS trial. In this publication, overall survival (OS) and all other secondary endpoints were evaluated. The ARAMIS trial looked at the use of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer. Drs. Wallis an...
|
- Details
- Following a presentation at the ASCO 2020 Annual Meeting, Neal Shore discusses the results of the phase III ARAMIS trial which randomized over 1,500 patients with non-metastatic castration-resistant prostate cancer to 600 mg of darolutamide orally twice daily with ADT, versus a placebo-controlled combination with ADT. The study had a composite endpoint of overall survival and radiographic progress...
|
